New triple therapy aims to tame tough pancreatic cancer

NCT ID NCT06229496

Recruiting now Disease control Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

First seen May 24, 2026 · Last updated May 24, 2026

Summary

This study is testing a new combination of three drugs (S-1, nab-paclitaxel, and gemcitabine) in people whose pancreatic cancer has spread to other parts of the body. The goal is to find the safest and most effective dose and to see how well the drugs shrink tumors. About 70 participants will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Chang-Gung Memorial Hospital, Kaohsiung Branch
NOT_YET_RECRUITING

Kaohsiung City, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
Chang-Gung Memorial Hospital, Linkou Branch
RECRUITING

Taoyuan, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
Chiayi Chung Gung Memmorial Hospital
RECRUITING

Chiayi City, 613, Taiwan

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

METASTATIC PANCREATIC ADENOCARCINOMA